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Abstract: The rapid advancement of molecular tools in the past 15 years has allowed for the 
retrospective discovery of several new respiratory viruses as well as the characterization of 
novel emergent strains. The inability to characterize the etiological origins of respiratory 
conditions, particularly in children, led several researchers to pursue the discovery of the 
underlying etiology of disease. In 2001, this led to the discovery of human metapneumovirus 
(hMPV) and soon following that the outbreak of Severe Acute Respiratory Syndrome 
coronavirus (SARS-CoV) promoted an increased interest in coronavirology and the latter 
discovery of human coronavirus (HCoV) NL63 and HCoV-HKU1. Human bocavirus, with 
its four separate lineages, discovered in 2005, has been linked to acute respiratory tract 
infections and gastrointestinal complications. Middle East Respiratory Syndrome coronavirus 
(MERS-CoV) represents the most recent outbreak of a completely novel respiratory virus, 
which occurred in Saudi Arabia in 2012 and presents a significant threat to human health. 
This review will detail the most current clinical and epidemiological findings to all 
respiratory viruses discovered since 2001. 
Keywords: respiratory viruses; human coronaviruses; hMPV; bocavirus;  
SARS-CoV; MERS. 
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1. Introduction 
Viral infections of the upper and lower respiratory tract are among the most common illness in  
humans. Children and infants bear the major burden of infection, typically presenting with 5 to 6 episodes 
annually [1]. These infections are often associated with significant patient morbidity and related 
mortality. For this reason, URTIs and LRTIs represents the leading cause of death in children younger 
than five years of age worldwide [2,3]; this accounts for approximately 4 million deaths annually [4]. 
Acute respiratory tract disease is the leading cause of hospitalization in children and febrile episodes in 
infants younger than three months of age [5,6]. 
Bacteria only represent approximately 10% of all upper respiratory tract infections with the 
subsequent 90% of infections caused by respiratory viruses [7]. Despite the viral aetiological origin of 
most respiratory infections, antibiotics are often prescribed in the treatment of such diseases [8], 
exacerbating antibiotic abuse. The morbidity and fiscal implications associated with respiratory 
infections are significant, with approximately 500 million cases reported in the United States alone each 
year with subsequent direct and indirect costs to the US economy estimated at $40 billion annually [2]. 
The burden of respiratory tract infections is increased in patients with chronic comorbidities or  
clinical risk factors including asthma [9], chronic obstructive pulmonary disease (COPD) [10], young, 
elderly [11] and immunocompromised [12,13]. 
The viruses primarily associated with upper respiratory tract infections commonly include 
rhinoviruses, enteroviruses, adenoviruses, parainfluenza viruses (PIV), influenza viruses, respiratory 
syncytial viruses (RSV) and coronaviruses [3,8,14,15]. In recent years six new human respiratory viruses 
have been reported including human metapneumovirus (hMPV) [16], bocavirus and four new  
human coronaviruses including Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), human 
coronavirus NL63 (HCoV-NL63), HCoV-HKU1 and Middle East Respiratory Syndrome coronavirus 
(MERS-CoV). This review will detail these newly discovered and emerging respiratory viruses. 
2. Human Coronaviruses 
Coronaviruses affect a diverse group of animal hosts, and cause a plethora of diseases in  
animals including progressive peritonitis, acute and chronic hepatitis, gastroenteritis, nephritis, and 
encephalitis [17]. In humans coronavirus infection results in respiratory tract complications with  
varying degree of severity and have been associated with gastroenteritis. Four human coronaviruses 
(HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1) are endemic in the human population and 
are mainly associated with mild, self-limiting respiratory illnesses. Another two human coronaviruses, 
namely SARS-CoV and MERS-CoV cause severe respiratory syndromes and present a significant threat 
with their high fatality rates. 
The first human coronaviruses were identified in the 1960s by Tyrell and Bynoe who passaged a 
virus, named B814, in human embryonic tracheal organ cultures. When this virus was inoculated 
intranasally into human volunteers, common cold-like symptoms were produced [18,19]. Hamre and 
Procknow (1966) later isolated a virus, which they were able to grow in tissue culture, from subjects 
presenting with symptoms of the common cold. The virus was later named human coronavirus 229E 
(HCoV-229E) [20]. 
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All of these viruses, including B814 and HCoV-229E, were ether-sensitive, indicating the presence 
of a lipid covering. McIntosh et al. (1967) later recovered several ether-sensitive viruses from human 
respiratory tracts, which were grown in organ culture. These viruses were termed “OC” viruses to 
indicate passage in organ culture. Under electron microscopy all of these viruses had morphologies 
similar to several other animal viruses previously identified, namely IBV, MHV and TGEV [21].  
These viruses were later classified as coronaviruses, which was accepted as a new genus in 1975. 
Unfortunately, many of the clinical samples collected and stored in the 1960s, which were positive for 
coronavirus-like particles, were subsequently lost. Therefore, until the identification of SARS-CoV in 
2003, the study of human coronaviruses was restricted to research of HCoV-229E and HCoV-OC43 [17] 
despite the clear evidence of further coronavirus strains [22,23]. 
2.1. Severe Acute Respiratory Syndrome Coronavirus: Emergence of a Novel Coronavirus 
An outbreak of atypical pneumonia was first reported to the WHO in February 2003. By the  
15th of March the disease was named Severe Acute Respiratory Syndrome (SARS) [24–26] and by  
the 27th of March the causative agent was identified as a completely novel coronavirus, termed  
SARS-CoV [27–29]. From November 2002 to July 2003 a total of 8098 patients, in 25 countries, were 
affected by the atypical pneumonia which resulted in 774 deaths globally. The mortality rates were 
drastically increased in certain population [30] and age [31] groups to as high as 40%–55%. Further local 
outbreaks were reported in Singapore, Taiwan and Beijing from accidental laboratory exposure and 
animal to human transmission in Guangzhou in late 2003 and early 2004 [32]. This was directly related 
to the lifting of a ban on serving palm civets in wet markets and restaurants, which was implemented 
during the SARS outbreak [33]. 
No antiviral agents were available during the outbreak to combat infection with SARS-CoV [34] and 
supportive care and administration of antibiotics to combat secondary bacterial infection was the  
primary treatment regimen [35]. With this it is clear that the control of the SARS-CoV outbreak is thanks, 
almost entirely, to a highly effective global public health response [36], where intense contact tracing 
and quarantine of suspected and infected patients were key in the control of the SARS outbreak [35]. 
SARS-CoV is no longer in human circulation but the discovery of SARS-like-CoV in bats and other 
mammals does present a potential threat of re-emergence [37]. 
The outbreak of SARS-CoV was most-likely linked to a zoonotic event in the live animal  
markets of China. Himalayan palm civets and raccoon dogs were the first animals identified to carry a 
SARS-like-CoV with 99.8% nucleotide homology to human SARS-CoV [38]. Further studies of wild 
animals in the areas around Hong Kong identified a further SARS-like-CoV in Chinese  
horseshoe bats (genus Rhinolophus), which shared a sequence identity of 87%–92% with human  
SARS-CoV [39,40]. Horseshoe bats therefore appear to be the natural reservoir of the ancestral  
SARS-CoV, with civets providing the intermediate amplification host with subsequent spread to  
animal handlers in the wet markets of Guangzhou. Under positive selection pressures within the  
human host SARS-CoV became readily transmissible and allowed for fast and effective spread from 
human-to-human with subsequent international dissemination by the index case in Hong Kong [41]. 
Analysis of genomic sequences from viral isolates obtained in the early, mid and late stages of the 
epidemic clearly indicate positive and purifying selective pressures followed by stabilization [33]. 
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Seroepidemiological studies have shown that 40% of wild animal traders and 20% of people responsible 
for the slaughtering of animals in the region where human SARS was thought to originate, were 
seropositive for SARS-CoV, although all cases were asymptomatic. This indicates that these people were 
previously exposed to a SARS-like-CoV, which resulted in asymptomatic infection [38]. 
SARS presents as an atypical pneumonia [42,43], with pneumocytes being the primary target of 
infection. Infection results in haemorrhagic inflammation in most pulmonary alveoli with alveolar 
thickening, diffuse alveolar damage, desquamation of pneumocytes, formation of hyaline membranes 
and multinucleated pneumocytes with capillary engorgement and microthrombosis [44]. Approximately 
60% of patients deteriorated in the second week of infection, presenting with persistent fever, dyspnoea 
and oxygen desaturation [29]. Approximately 20%–30% of patients were subsequently admitted to 
intensive care, where mechanical ventilation was necessary [45]. A surprising finding with the SARS 
outbreak was that it was not as great a threat to infants and children [33,46]. Clinical presentation was 
less severe in infants and no children aged between 1 and 12 required intensive care or mechanical 
ventilation [47,48]. This is in sharp contrast to the age related burden of other respiratory infections and 
the underlying biological mechanism remains unclear [49]. 
A family of viruses that were previously understood to cause mild, self-limiting upper respiratory 
tract infections was showcased by the SARS-CoV outbreak to be a significant threat to global public 
health. The economic losses brought on by the SARS pandemic was estimated to be in the region  
40 billion dollars [50] with Hong Kong bearing a significant proportion of the losses. Tourism, 
entertainment and restaurant industries in the area recorded up to 80% loss in business. The pressure on 
healthcare facilities in affected areas was substantially exacerbated by the spread to healthcare workers. 
Several hospitals were forced to close to new admissions as large numbers of staff became infected with 
SARS-CoV. To view this as an isolated incidence would be naïve and the potential for the emergence 
and re-emergence of new and existing infectious agents poses a probable risk. Understanding the  
SARS-CoV outbreak has provided immense knowledge and an excellent model to replicate in the event 
of further outbreaks of communicable diseases. 
2.2. Human Coronavirus NL63 and HKU1: Discovery of Existing Coronaviruses 
2.2.1. Human Coronavirus NL63 
In 2003 a 7 month old child presenting with bronchiolitis and conjunctivitis was screened for  
several respiratory viruses to identify the causative agent, with all diagnostics yielding negative results. 
The group led by Lia van der Hoek then used a modified cDNA amplified restriction fragment-length 
polymorphism (cDNA-AFLP) technique (Virus-Discovery-cDNA-AFLP or VIDISCA), to identify the 
causative agent. Briefly, the technique utilizes reverse transcription-PCR of viral RNA with subsequent 
restriction digest of the cDNA using frequently cutting restriction enzymes. Since the restriction sites 
are selected and therefore known, the resultant “sticky ends” can be ligated into anchors for amplification 
and sequencing with specific primers. The results showed highest sequence similarities with known 
coronaviruses, but with significant sequence divergence indicating the discovery of a new coronavirus 
species, later named human coronavirus NL63 [51]. 
Viruses 2015, 7 1000 
 
 
At about the same time, two other independent groups identified essentially the same virus [52,53]. 
Shortly after the van der Hoek paper [51], a novel coronavirus that replicated efficiently in tertiary 
monkey kidney and Vero cells, was retrospectively isolated from a nose swab sample collected in 1988 
from an 8 month-old boy presenting with pneumonia. This virus was reported to be similar to  
HCoV-NL63 and named HCoV-NL [52]. In 2005, Esper et al. (2005) also reported the identification of 
a novel coronavirus isolated in New Haven, Connecticut, which was named HCoV-NH. This novel virus 
was identified by PCR which was adapted to amplify a conserved region within the replicase 1a or pol 
gene [53]. Subsequent sequence analysis showed that these three viruses were essentially the same virus 
or variants thereof [53,54]. 
It is obvious that HCoV-NL63 has been circulating in the human population since before 1988 [52]. 
In fact, molecular clock analyses have shown that HCoV-NL63 and HCoV-229E diverged from a most 
recent common ancestor, in a zoonotic event, approximately 563 to 822 years ago [55]. HCoV-NL63 
later diverged into two lineages with subsequent recombination of the two lineages during co-infection. 
This frequent recombination has given HCoV-NL63 a mosaic structured genome with multiple 
recombination sites [56]. 
2.2.2. Human Coronavirus HKU1 
A 71 year old male patient from China was admitted to hospital with pneumonia in January 2004. 
Viral cultures, RT-PCR and direct antigen detection from nasopharyngeal aspirate were all negative for 
respiratory viruses. A pan-coronavirus RT-PCR targeting a conserved region of the pol gene confirmed 
the presence of a coronavirus however attempts to culture the causative agent were all unsuccessful. 
Sequencing the gene segment amplified by the pan-coronavirus assay indicated a high homology to other 
viruses of the βCoV genus including HCoV-OC43 but of novel origin. The human coronavirus, termed 
HCoV-HKU1, was later isolated from another female patient. Efforts to culture the virus had posed 
complicated and the complete genome was isolated, amplified and sequenced directly from RNA 
extracted from a nasopharyngeal aspirate [57]. Successful propagation of the virus was achieved recently 
in human ciliated airway epithelial cells [58] but culturing of HCoV-HKU1 still remains a daunting task. 
The presence of the HE gene further characterizes HCoV-HKU1 as belonging to the βCoV genus. 
Since the discovery of HCoV-HKU1, its prevalence has shown a global distribution and retrospective 
analysis on stored nasopharyngeal aspirates have confirmed its existence since 1995 [59]; however, 
phylogenetic analysis suggests a much earlier divergence. 
2.3. MERS-CoV: 10 Years on from SARS 
June 2012 saw the most recent emergence of a completely novel strain of human coronavirus.  
A sputum sample was collected from a 60 year old male patient presenting with severe respiratory 
disease in the Dr. Soliman Fakeeh Hospital in Jeddah, Saudi Arabia. Viral assays frequently used could 
not identify any aetiological agent responsible for the disease. The sputum sample was sent to  
Dr. Ron Fouchier at the Erasmus Medical College in Rotterdam, Netherlands, where the virus was 
identified as a novel coronavirus, provisionally termed HCoV-EMC (human coronavirus Erasmus 
Medical College). The patient later succumbed to the disease with acute pneumonia and subsequent renal 
failure [60]. A retrospective study further traced the virus back to April 2012 where an outbreak of 
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pneumonia, resulting in two fatalities, occurred in health care workers in an intensive care unit in  
Zarqa, Jordan [61]. 
Since the initial discovery, several new isolates were identified and described in scientific literature, 
databases and media under various names. This provoked the convening of the Coronavirus Study  
Group to introduce a naming convention and avoid confusion within the research field, health care  
authorities, governments and general public. The name Middle East Respiratory Syndrome coronavirus 
(MERS-CoV) was coined and has been widely accepted by the discoverers of the virus and pioneers of 
the field, the WHO and Saudi Ministry of Health [61]. 
Primary infections, to which all cases were linked directly or indirectly, occurred in Middle Eastern 
countries including Saudi Arabia, Qatar, Jordan, Oman and United Arab Emirates and subsequently 
spread to United Kingdom, Tunisia, France, Italy and Germany with Egypt and the United States  
recently reporting their first laboratory confirmed cases [62,63]. The potential of widespread pandemic 
outbreak is thought to be low as human-to-human transmission is largely inefficient [64] and only 
reported in close, sustained contact [65] such as within families [66], healthcare workers [67] and as 
nosocomial transmission [68], especially if the patient represents with comorbidities. There has been no 
evidence to suggest sustained community transmission [62]. The ever increasing case numbers and 
countries affected by the disease however suggests MERS-CoV does represent potential for widespread, 
global outbreak [69]. 
From the first reported case in June 2012, until 7 February 2014, a total of 182 cases had been reported 
with 79 fatalities. According to the latest figures available from the WHO, as of 11 June 2014, the  
virus had resulted in a total of 699 laboratory confirmed cases with a total of 209 fatalities [70]. These 
statistics indicate that within a 4 month period case numbers had more than trebled suggesting the virus 
is far from controlled. The fatality rate of 30% is also substantially increased in patients with 
comorbidities, with a large number of reported cases being identified in immunocompromised patients 
or those with underlying disease [68,71] and a severe threat of nosocomial transmission has been 
demonstrated [72]. Clinical presentation is similar to SARS and includes a spectrum of respiratory 
diseases with the most common symptoms including cough, fever and gastrointestinal symptoms [69] 
before progressing to pneumonia [68]. Acute respiratory distress syndrome (ARDS), renal failure, 
pericarditis and disseminated intravascular coagulation have also been reported [69]. The potential of 
widespread pandemic outbreak is thought to be low as human-to-human transmission is largely 
inefficient [64] and only reported in close, sustained contact [65] such as within families [66], healthcare 
workers [67] and as nosocomial transmission [68], especially if the patient presents with comorbidities. 
There has been no evidence to suggest sustained community transmission [62]. The ever increasing case 
numbers and countries affected by the disease however suggests that MERS-CoV does represent 
potential for widespread, global outbreak [69]. 
The inefficient spread between infected patients strongly suggests zoonotic transmission, however 
over two years on from the initial discovery of MERS-CoV it is still unclear where it originated from 
and how it infects humans. During the outbreak of SARS-CoV the identification of the wet markets of 
China as the probable source greatly contributed to the control of the disease [38]. This highlights the 
importance in identifying the origins of disease outbreak. Phylogenetic analysis places it in the same 
genus as SARS-CoV but within a new lineage, 2c. The closest detectable relatives suggests origins from 
bat coronavirus species with relative high sequence homology between Bat-CoV HKU4 and HKU5 in 
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China [73], VM314 in the Netherlands [74] and a recently discovered isolate from South Africa [75]. 
Assuming that bats also form the immediate source is improbable and as with SARS-CoV an 
intermediate animal host species for transmission to humans is of greater likelihood [61]. High levels of 
neutralizing antibodies, viral RNA and infectious viruses have been discovered in dromedary camels 
suggesting a potential for camels to form the source for human transmission [76–79]. A recent study 
identified identical single nucleotide polymorphisms in a sequence of MERS-CoV isolated from an 
infected patient and camel, which was cared for by the patient. Phylogenetic analysis of these two 
sequences supported the conclusion that transmission occurred between patient and camel, however the 
direction of transmission could not be confirmed [80]. It has since been proven that a patient who 
succumbed to MERS-CoV infection obtained the virus directly from his camel herd. The direction of 
transmission was confirmed as camel-to-human by serological analysis [81]. These facts strongly 
contribute to an increasingly popular hypothesis that MERS-CoV infections in humans are directly 
acquired from camels, however very few patients have had reported contact with camels. Many residents 
of the Arabian Peninsula frequently consume unpasteurized camel milk and this has been suggested  
as a potential source as the virus has been detected and can remain viable for prolonged periods in  
milk [82,83]. The WHO, Saudi Arabia and Qatar have recently issued warnings and recommended 
against consuming unpasteurized camel milk and to be cautious when interacting with dromedary  
camels [84]. 
The outbreak of SARS-CoV in 2003 and MERS-CoV less than 10 years later highlights the significant 
threat of coronaviruses to humans and confirms that the SARS outbreak was not an isolated incident. 
With the ever increasing diversity of animal coronavirus species, especially within bats, the likelihood 
of recombination leading to future outbreaks is high and the threat of potential pandemics is real as 
highly pathogenic coronaviruses continue to spill over from zoonotic sources into the human population. 
Misdiagnosis of these outbreaks pose a further substantial threat to healthcare workers with nosocomial 
spread to other patients putting further pressure on an already strained healthcare system. Understanding 
the dynamics and molecular characteristics of human coronaviruses currently in circulation and how 
they emerge, infect and cause disease, we can be better prepared for future pandemics allowing for 
improved response, management and treatment of related conditions. Table 1 summarizes the human 
coronaviruses discovered since 2003. 
Table 1. Human coronaviruses identified since 2003. 
Name Year Discovered Emergent/Previously Circulating Fatality Rate Current Circulation 
SARS-CoV 2003 Emergent ~10% No 
HCoV-NL63 2003 Previously circulating low Yes 
HCoV-HKU1 2004 Previously circulating low Yes 
MERS-CoV 2012 Emergent ~30% Yes 
2.4. Clinical Importance of Non-Severe Human Coronaviruses 
The clinical presentation of human coronaviruses clearly follows two distinct lines of progression. 
SARS-CoV and MERS-CoV present with severe respiratory complications and often multisystem 
involvement with renal failure and enteric symptoms. The high fatality rates associated with these 
infections is not reflected in the remaining four human coronaviruses, HCoV-229E, HCoV-OC43, 
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HCoV-NL63 and HCoV-HKU1. The clinical importance of SARS-CoV and MERS-CoV are evident 
and discussed in detail in previous sections allowing for the presentation of the involvement of the 
remaining non-severe human coronaviruses and there implications in human health. 
2.4.1. Clinical Presentation of Human Coronavirus Infection 
The clinical presentation of these four non-severe human coronaviruses is largely identical and 
indistinguishable symptomatically, commonly presenting with rhinorrhoea, sore throat, cough and  
fever [85,86]. Majority of infections are associated with self-limiting upper respiratory tract disease or 
“the common cold” but can also present with high morbidity outcomes of the lower respiratory tract 
including bronchiolitis, pneumonia, [87–89], asthmatic exacerbations [9] acute exacerbations of chronic 
obstructive pulmonary disease (COPD) [10] and croup in HCoV-NL63 infected patients [90]. A report 
by Esper et al. found a correlation between HCoV-NL63 infections and Kawasaki disease [91], although 
other studies could not replicate the association [92–94]. Febrile seizures have been reported for most 
human coronaviruses but the significance of HCoV-HKU1 is alarming with one study indicating that 
50% of patients infected with HCoV-HKU1 experience febrile seizures [9]. 
2.4.2. Prevalence and Distribution of Human Coronaviruses 
Human coronaviruses affect all age groups [85,86] but elicit more serious disease in young, elderly 
and immunecompromized [87,95,96], frequently resulting in hospitalization. Reports on the prevalence 
of human coronaviruses and their association with upper and lower respiratory tract disease vary but 
range between 3.3% and 16% [85,86,95,97]. Over 70% of the general public has seroconverted towards 
all four non-severe human coronaviruses with primary infection shown to occur in childhood [98] and 
reinfection occurring throughout life [95]. Given the high prevalence of respiratory infections, human 
coronaviruses represent a substantial disease burden which is exacerbated by the high implications of 
healthcare workers in coronavirus outbreaks [97]. 
2.4.3. Human Coronaviruses Frequently Present with Co-Infection 
High rates of co-infection with other respiratory viruses are commonly reported [85,86,95,99]. 
Viruses frequently associated with co-infection include enterovirus, rhinovirus and PIV [100] however 
reports of co-infection with two human coronaviruses are limited. Dijkman et al. recently demonstrated 
that HCoV-OC43 and HCoV-NL63 may elicit immunity that protects against HCoV-HKU1 and  
HCoV-229E, respectively [101]. Clinical progression and outcomes of disease in patients presenting 
with co-infection are however similar to patients presenting with mono-infection [85,95]. There is also 
no substantial difference in coronaviral load between co-infected and mono-infected patients.  
No substantial difference in disease progression in co-infected versus mono-infected patients has been 
reported and therefore understood to have little impact; however, the role in facilitation of infection of 
one respiratory virus by another is still speculative [95]. 
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2.4.4. Seasonal Distribution 
All four human coronaviruses are endemic worldwide but the prevalence, regional distribution and 
pathogenicity of individual human coronaviruses is unclear and highly subjective on study conducted 
with parameters including population sampled, respiratory sample collected, sensitivity of diagnostic 
assay used, region where study was conducted and duration of the study playing a substantial role in 
epidemiological findings. A common finding in majority of studies conducted is the increased 
prevalence of human coronaviruses during winter months in temperate climates [95,97]. However even 
this has shown to be geographically dependent with a spring/summer predominance in subtropical and 
tropical climates [9,102]. Biennial outbreaks are frequently reported [85,95,99,100] for all strains of  
non-severe human coronaviruses. 
3. Human Metapneumovirus (hMPV) 
In 2001 a previously undiscovered virus was identified in 28 epidemiologically distinct patients in 
the Netherlands. Patient symptoms were similar to those infected with RSV and, several patients required 
hospitalization and mechanical ventilation. Viral isolates were cultured in tertiary monkey kidney (tMK) 
cells and cytopathic effects caused by the virus were largely identical to those caused by RSV. Electron 
microscopy of infected cell supernatants revealed paramyxovirus-like particles; however, RT-PCR 
assays to detect known paramyxoviruses were all negative. The low stringency of the assays used 
indicated a currently unknown, genetically distinct virus. A RAP-PCR assay was then utilized to obtain 
sequence information of the unknown virus and fragments amplified by the RAP-PCR allowed for 
further sequencing of the 3’-end of the genome. Based on the sequence homology and gene organization, 
the unidentified virus displayed closest homology with avian pneumovirus, but to be a tentative new 
member of the Metapneumovirus genus and the first virus in the genus to infect humans, provisionally 
termed human metapneumovirus (hMPV) [16]. 
3.1. Clinical Presentation of hMPV Infection 
Symptomatic differentiation between hMPV and other respiratory viruses cannot be made as there is 
a significant overlap in clinical presentation [103,104]. The most common presentation of hMPV in 
children includes complications of the upper respiratory tract with rhinorrhoea, cough and fever [105]. 
Acute otitis media is also frequently reported [106,107] and conjunctivitis, rash, diarrhea and vomiting 
are reported but infrequently [103]. Bronchiolitis, pneumonia, croup and asthmatic exacerbations are the 
most frequently associated lower respiratory tract complications [108] and viral load is directly 
associated with disease severity [109]. hMPV infection in the young and elderly frequently requires 
hospitalization and fatalities have been reported in the elderly [110,111]. An increased morbidity in 
elderly patients with a delayed clearance of symptoms has been reported and is likely related to the age 
related impairment of the innate and adaptive immunity [103] or an over stimulated immune response 
leading to inflammation [112]. Elderly patients requiring hospitalization most frequently present with 
acute bronchitis, COPD exacerbations, pneumonia and congestive heart failure [113]. In healthy adults 
asymptomatic infections or cold- and flu-like symptoms are the most prevalent presentation [114]. 
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3.2. Coinfections with hMPV 
The pathogenesis of hMPV infection is strongly affected by bacterial coinfections with 
pneumococcus. One study has shown that administration of a conjugate pneumococcal vaccine is 
sufficient to reduce the incidence of hMPV infection of the lower respiratory tract and the incidence of 
clinical pneumonia in both HIV positive and negative patients [115]. These finding suggest that the 
incidence of hospitalizations in hMPV infections may be decreased by vaccination with a conjugate 
pneumococcal vaccine. Another case report of severe respiratory failure was found to be caused by 
coinfection with hMPV and Streptococcus pneumonia in a 64 year old patient [116]. Both in vitro and 
in vivo studies have shown that infection with hMPV facilitates adhesion of pneumococcal bacteria, 
which may provide an explanation for the coinfection with pneumococcal strains and hMPV [117]. 
Viral coinfections between hMPV and RSV have been reported, but remain a contentious issue.  
The typical seasonal overlap of the two viruses has been suggested to promote viral coinfection.  
One study reported a 10-fold increase in risk of admission to an intensive care unit in pediatric patients 
coinfected with RSV and hMPV and associated the dual infection as capable of augmenting severe 
bronchiolitis [118]. Other studies do not support this finding and further report a decreased correlation 
between hMPV-RSV coinfections and hospitalization and additionally lists dual infection, along with 
breastfeeding, as having protective effects [119]. 
3.3. Epidemiology of hMPV 
Although hMPV was only discovered in 2001, it has been shown by phylogenetic analysis to have 
been in existence for approximately 50 years [120,121]. Soon after the discovery of hMPV, it was 
evident that two lineages, A and B, existed. These two lineages were further subdivided into two 
sublineages per lineage, A1-A2 and B1-B2 [16]. A recent report analyzing sequence divergence of the 
attachment and fusion surface glycoproteins indicates the presence of five sublineages, namely A1, A2a, 
A2b, B1 and B2 [122]. From long term retrospective studies it was evident that these lineages are not  
restricted to certain locations or times and that multiple lineages can exist in the same location and  
period [108,123]. It has also become evident that old sublineages may be replaced by new variants [103]. 
Disease progression or varying clinical outcomes related to different lineages of hMPV has become a 
contentious issue. Several studies have reported that lineage A presents with more severe clinical 
outcomes [124–126] where the same is reported for lineage B by other groups [127,128]. It has been 
further reported that there is no difference in disease outcomes related to the two lineages [108,129,130]. 
Between 7% and 19% of all cases of respiratory infections in children are caused by hMPV, in both 
hospitalized and outpatients [108,131,132] and has been reported to be the second most frequently 
identified virus in respiratory tract infections [133]. Extrapolation of consensus data suggests a total of 
20 000 hospital and one million clinic visits annually in the US among children younger than 5 [131]. 
Children hospitalized with hMPV infections are also more likely to present with pneumonia or asthma 
and required longer stay in intensive care units with supplemental oxygen, when compared to other 
respiratory viruses [131]. Seroprevalence studies indicates that 100% of young adults are seropositive 
for hMPV with stable neutralizing titres, which further suggests that reinfection occurs throughout  
life [16], with a potential for genetic variation between clades promoting reinfection [108]. 
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hMPV has a worldwide distribution and affects all age groups but predominantly affects young, 
elderly and immunocompromised patients [111], with children younger than five years of age being most 
susceptible to infection [134]. Children and adults with underlying or chronic conditions such as asthma, 
chronic lung disease, congenital heart disease, cancer or COPD are more likely to be hospitalized with 
hMPV infection [131]. Infection with hMPV occurs throughout the year but seasonal prevalence in late 
winter and spring has been observed and coincides with the peak of RSV infection [131,135–137]. 
4. Human Bocavirus 
The first human bocavirus (hBoV) was discovered in 2005 from nasopharyngeal aspirates of  
282 patients with unresolved lower respiratory tract infections in Sweden. Researchers utilized a novel 
technique which included steps of DNase treatment to exclude contaminating, or non-viral, nucleic acids 
followed by PCR amplification by nonspecific primers. The PCR-products were subsequently cloned 
with large-scale sequencing of the clones. Bioinformatic analysis of generated sequence data yielded  
the discovery of a new parvovirus with a high homology to bovine and canine minute parvoviruses.  
The genus name Bocavirus was in fact derived from the species infected by the known virus strains, 
namely bovine and canine. The new virus was named hBoV1 and was the first virus to be discovered by 
molecular virus screening [138]. Three additional species of hBoV were later discovered in 2010 and 
added to the genus; these were named hBoV2, hBoV3 and hBoV4 [139–141]. 
4.1. Clinical Significance of hBoV 
HBoV1 is a respiratory pathogen affecting all regions of the globe and is associated with approximately 
2%–19% of all upper and lower respiratory tract conditions [142–144]. HBoV1 productively infects 
human airway epithelium cell cultures and leads to damage of airway epithelial cells [145–147],  
which supports clinical observations that infection does result in respiratory disease. In contrast,  
hBoV2–4, are found in the gastrointestinal tract and hBoV2, and possibly hBoV3, are associated with 
gastroenteritis [139,148–150]. Interestingly, HBoV2 is the only enteric bocavirus to be isolated from 
nasopharygeal aspirates and may, therefore, also be associated with respiratory disease [151,152]. 
HBoV1 is detected in all age groups, but predominantly in young children between the ages of  
6–24 months [143,153,154] and is rarely detected in adults [155–159]. Transmission and infection 
occurs throughout the year, but predominantly during winter and spring months [158,160–162]. 
Seroprevalence studies suggest that maternal antibodies, which provide protection, are present in infants 
younger than 2 months of age [163,164], after which seropositivity decreases with low levels of detection 
until 6–12 months. Virtually 100% of children aged 6 are seroconverted for hBoV1 and as reinfection 
occurs throughout life this remains into adulthood [143,163–166]. The presence of the three enteric 
bocaviruses does however complicate the findings of seroconversion as cross-reactivity does exist [166]. 
As with many respiratory viruses, clinical differentiation with hBoV1 infection is not possible by 
symptomatic presentation [8]. Common features of infection of the upper respiratory tract include 
common cold-like symptoms with cough, rhinorrhoea and acute otitis media [167]. Infection of the lower 
respiratory tract in children is associated with pneumonia, acute wheezing, asthmatic exacerbations and 
bronchiolitis [160,162,168–170], but life-threatening complications are rare with hBoV1 infection [143]. 
Although hBoV1 has been isolated from stool samples, there is no statistical evidence to associate 
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hBoV1 with gastrointestinal disease [139]. HBoV1 has not only been found in the upper and  
lower respiratory tract and gastrointestinal specimens, but also in urine samples, serum, saliva, and 
tonsils [143]. Rather than having a role in disease pathogenesis, this viraemia and systemic spread may 
be a feature common to all Parvoviruses as they require proliferating host cells for replication [138]. 
Interestingly, hBoV appears to be more than just a respiratory or gastrointestinal virus. In a recent 
study, hBoV was identified in 18.3% of lung (n = 11/60) and 20.5% of colorectal (n = 9/44) tumors 
screened. Unfortunately, the study did not investigate whether the hBoV genomes were in fact 
incorporated into the host genome as reported for other known Parvoviruses. Therefore, based on their 
observations as well as previous studies on other parvoviruses, the authors speculate that hBoV could 
contribute to the development of some lung and colorectal tumors. However, they do also acknowledge 
that these tumors could simply be providing an optimal environment for hBoV replication and more 
conclusive studies are required to resolve this issue [171]. 
4.2. Coinfection with hBoV1 
HBoV1 has been associated with a prolonged period of persistence in the mucosa of the respiratory 
tract. This prolonged presence has possibly led to a high frequency of coinfection found with hBoV1 
infections of the both the upper and lower respiratory tract [142,157,158]. The high rate of detection of 
multiple respiratory viruses within up to 83% of respiratory specimens, and the presence of 
asymptomatic hBoV1 infections, does complicate the determination of the actual pathogenic role of 
HBoV [143]. High viral load is statistically associated with symptoms [172] and this may therefore be a 
better indication of coinfections which are related to disease severity or symptomatic presentation. It has 
been further suggested that patients presenting with viraemia are better candidates to assess the 
symptoms of disease when compared to investigations of respiratory secretions [172]. The effects and 
mechanisms of latency, persistence, reactivation and reinfection are however poorly understood and 
therefore its effects on coinfection and its contribution to active disease cannot be accurately stated [173]. 
5. Conclusions 
The etiological agents of 12%–39% of lower respiratory tract infections still remain to be  
identified [138,158]. These results may vary significantly depending on the sensitivity of the diagnostic 
assay used, respiratory site sampled and even geographical location of the study but it does suggest that 
many uncharacterized respiratory pathogens could still remain elusive awaiting discovery. The vast 
improvements in molecular techniques within the past decade have however led to the discovery of four 
previously circulating respiratory viruses and also the rapid characterization of two completely novel 
viruses, namely SARS-CoV and MERS-CoV. All these viruses have varying but significant impact on 
human health and the potential for outbreak of completely novel, emergent respiratory viruses, seen with 
SARS and MERS, poses their own unique threats. Lessons learned from these viruses, and others 
currently in circulation, provide health care authorities and scientists with suitable expertise and 
knowledge to rapidly identify and combat novel respiratory viruses and as our techniques improve we 
will be in a position to characterize those viruses that are currently difficult to isolate and identify. 
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